This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients
European Journal of Clinical Pharmacology Open Access 06 February 2024
-
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy
Diabetology & Metabolic Syndrome Open Access 06 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022190 (2020)
Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet https://doi.org/10.1016/S0140-6736(20)31824-9 (2020)
Related article
Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-020-0406-8 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, G.B. Empagliflozin improves outcomes in HFrEF regardless of diabetic status. Nat Rev Cardiol 17, 681 (2020). https://doi.org/10.1038/s41569-020-00455-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-020-00455-7
This article is cited by
-
Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients
European Journal of Clinical Pharmacology (2024)
-
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy
Diabetology & Metabolic Syndrome (2023)
-
Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
American Journal of Cardiovascular Drugs (2023)